Related Experiment Video
Updated: Jul 17, 2026
Molecular and Immunologic Techniques in a Genetically Engineered Mouse Model of Gastrointestinal Stromal Tumor
Published on: May 2, 2022
[Gastrointestinal stromal tumors (GIST)--a paradigm of successful targeted therapy of solid tumors]
Borislav Belev1, Damir Vrbanec, Marko Kralik
1Zavod za internisticku onkologiju, Klinika za otnkologiju, Zagreb, Hrvatska.
Abstract:
Gastrointestinal stromal tumors (GIST) have attracted basic scientists as well as clinicians in the last 10 years. The reason for this is explanation of the pathogenetic mechanism of tumor growth by activation of c-Kit protein, followed by a rationally designed suppressor, a drug named imatinib. It is the first successful therapy for solid tumors to date, although there are other ongoing studies of agents with targeted action on different molecules in different tumors. In 80% of patients there is a clinical benefit from imatinib trreatment. GIST shows great diversity in clinical presentation and some questions still remain, such as malignant potential and prognostic criteria in these tumors. Imatinib therapy demonstrates many favorable effects such as acceptable toxicity and relative mild side effects, excellent quality of life, good patient compliance, etc. There are ongoing trials of new agents designated for target molecules, which would hopefully show benefit after developing resistance to imatinib.
Insights
Gastrointestinal stromal tumors (GIST) are targeted by imatinib therapy, a breakthrough drug that benefits 80% of patients. Ongoing research explores new agents for imatinib-resistant GIST.
Area of Science:
- Oncology
- Molecular Biology
- Pharmacology
Context:
- Gastrointestinal stromal tumors (GIST) represent a significant area of research in oncology.
- The pathogenetic mechanism involving c-Kit protein activation has been elucidated.
- Imatinib has emerged as a targeted therapy for GIST.
Purpose:
- To review the current understanding and treatment of GIST.
- To highlight the efficacy and tolerability of imatinib therapy.
- To discuss ongoing research into novel therapeutic agents for GIST.
Summary:
- Imatinib therapy provides clinical benefit in 80% of GIST patients, demonstrating acceptable toxicity and good quality of life.
- GIST exhibits diverse clinical presentations, with ongoing questions regarding malignant potential and prognostic criteria.
- Research is actively exploring new targeted agents to overcome imatinib resistance.
Impact:
- Imatinib represents a paradigm shift in solid tumor treatment, offering a successful targeted therapy.
- Understanding GIST heterogeneity is crucial for refining prognostic criteria and treatment strategies.
- Future therapeutic strategies aim to improve outcomes for patients with advanced or resistant GIST.
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against specific...
02:57Targeted Cancer Therapies
There are several types of targeted therapies against specific...